Chatelut E - Search Results

1

Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancer.

Gandia P, Arellano C, Chalret du Rieu Q, Lochon I, Campone M, Pierga JY, Poublanc M, Hennebelle I, Filleron T, Chatelut E, Delord JP. Gandia P, et al. Among authors: chatelut e. Curr Clin Pharmacol. 2011 Nov;6(4):274-9. doi: 10.2174/157488411798375921. Curr Clin Pharmacol. 2011. PMID: 22082325 Clinical Trial.

2

Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma.

Chatelut E, Chevreau C, Blancy E, Lequellec A, Canal P, Roche H, Houin G, Bugat R. Chatelut E, et al. Cancer Chemother Pharmacol. 1990;26(5):365-8. doi: 10.1007/BF02897295. Cancer Chemother Pharmacol. 1990. PMID: 2170043

3

[Relations between hematological toxicity and total and free plasma levels of etoposide in daily oral administration].

Lavit M, Chevreau C, Chatelut E, De Fenin V, Lochon I, Houin G, Bugat R, Canal P. Lavit M, et al. Among authors: chatelut e. Bull Cancer. 1995 Aug;82(8):660-4. Bull Cancer. 1995. PMID: 7492822 French.

4

A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer.

Chatelut E, Chevreau C, Brunner V, Martinez M, Houin G, Bugat R, Canal P. Chatelut E, et al. Cancer Chemother Pharmacol. 1995;35(5):391-6. doi: 10.1007/s002800050252. Cancer Chemother Pharmacol. 1995. PMID: 7850920 Clinical Trial.

5

Population pharmacokinetics of carboplatin in children.

Chatelut E, Boddy AV, Peng B, Rubie H, Lavit M, Dezeuze A, Pearson AD, Roché H, Robert A, Newell DR, Canal P. Chatelut E, et al. Clin Pharmacol Ther. 1996 Apr;59(4):436-43. doi: 10.1016/S0009-9236(96)90113-7. Clin Pharmacol Ther. 1996. PMID: 8612389 Clinical Trial.

6

[Bayesian estimation of pharmacokinetic parameters of etoposide].

Evene E, Chatelut E, Tranchand B, Canal P, Lochon I, Iliadis A, Ardiet CJ. Evene E, et al. Among authors: chatelut e. Bull Cancer. 1997 Jul;84(7):699-703. Bull Cancer. 1997. PMID: 9339195 Review. French.

7

Population pharmacokinetics of total and unbound etoposide.

Nguyen L, Chatelut E, Chevreau C, Tranchand B, Lochon I, Bachaud JM, Pujol A, Houin G, Bugat R, Canal P. Nguyen L, et al. Among authors: chatelut e. Cancer Chemother Pharmacol. 1998;41(2):125-32. doi: 10.1007/s002800050718. Cancer Chemother Pharmacol. 1998. PMID: 9443625

8

Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice.

Guichard S, Chatelut E, Lochon I, Bugat R, Mahjoubi M, Canal P. Guichard S, et al. Among authors: chatelut e. Cancer Chemother Pharmacol. 1998;42(2):165-70. doi: 10.1007/s002800050801. Cancer Chemother Pharmacol. 1998. PMID: 9654118

9

Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule.

Perdaems N, Bachaud JM, Rouzaud P, Murris-Espin M, Hermant C, Mihura J, Lochon I, Houin G, Canal P, Chatelut E. Perdaems N, et al. Among authors: chatelut e. Eur J Clin Pharmacol. 1998 Nov-Dec;54(9-10):677-83. doi: 10.1007/s002280050534. Eur J Clin Pharmacol. 1998. PMID: 9923567 Clinical Trial.

10

A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients.

Tranchand B, Amsellem C, Chatelut E, Freyer G, Iliadis A, Ligneau B, Trillet-Lenoir V, Canal P, Lochon I, Ardiet CJ. Tranchand B, et al. Among authors: chatelut e. Cancer Chemother Pharmacol. 1999;43(4):316-22. doi: 10.1007/s002800050901. Cancer Chemother Pharmacol. 1999. PMID: 10071983 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

244 results

Search Page

Filters